Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance (SPANDHA)

5. listopadu 2026 aktualizováno: Balachundhar Subramaniam, Beth Israel Deaconess Medical Center

This study will examine whether meditation and yogic breathing can alter brain fluid movement and waste clearance in healthy adults. It will also evaluate the GLYMPHOMETER, a new external forehead-worn device designed to objectively measure changes in brain fluid movement and exchange during meditation.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

The glymphatic system is a brain waste-clearance pathway that facilitates the movement of cerebrospinal fluid (CSF) and interstitial fluid and is thought to play an important role in maintaining brain homeostasis. Emerging evidence suggests that respiration, autonomic activity, and changes in cerebral blood flow may influence CSF dynamics and related neurofluid processes. However, the effects of voluntary breathing practices and meditation on these physiological mechanisms in humans remain incompletely understood.

The SPANDHA study will investigate whether structured yogic breathing (Pranayama; specifically Nadi Shuddhi) and/or meditation (Shoonya meditation) are associated with changes in neurofluid dynamics and related physiological measures. The study will use the GLYMPHOMETER, a forehead-mounted multimodal device designed to measure physiological signals associated with neurofluid coupling during naturalistic meditation and breathing practices. The system incorporates multi-wavelength electroencephalography (EEG) and near-infrared spectroscopy (NIRS) to characterize changes in cerebral electrical activity, cerebral hemodynamics, and neurofluid-related dynamics while participants engage in the interventions.

The study will enroll approximately 100 participants, including 50 novice and 50 experienced practitioners. Using a 2-sequence crossover, participants will complete two study visits involving meditation and yogic breathing conditions. The study will evaluate changes in measures of neurofluid dynamics, cerebral compliance, autonomic regulation including heart-rate variability (HRV), and EEG-derived brain states associated with the interventions. Participants will be stratified by experience level (novice/advance) and randomized within each stratum to one of the two intervention sequences.

A subset of participants will undergo additional validation assessments using phase-contrast magnetic resonance imaging (MRI) and blood-based biomarkers. These assessments will be used to examine the relationship between measurements obtained with the GLYMPHOMETER and established measures of CSF and cerebrovascular physiology.

The primary objective of the study is to characterize the acute physiological effects of meditation and yogic breathing on neurofluid dynamics and related brain and autonomic measures. The findings may provide preliminary evidence regarding the feasibility of using voluntary breathing and meditation practices to modulate physiological processes associated with glymphatic function and may inform future studies of non-pharmacological approaches to brain health.

Typ studie

Intervenční

Zápis (Odhadovaný)

120

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

25 let až 60 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Healthy adults, 25-60 years old.
  • Novice or Advanced as defined above.
  • Fluent in English.
  • Able to travel to BIDMC site for two days approximately 3-7 days apart.

Exclusion Criteria:

  • History of neurological and/or neurodegenerative disorders (e.g., epilepsy, stroke, mild cognitive impairment, dementia)
  • History of cardiovascular and respiratory illnesses
  • History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder)
  • Currently diagnosed mental health issues (e.g., anxiety, depression)
  • Current use of psychoactive medications, including medications prescribed for anxiety, depression, or other psychiatric conditions, or current use of stimulants or other medications that may substantially affect central nervous system function or study outcomes.
  • Skin ailments, abrasions or contusions, particularly located on the forehead and face

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Jiný
  • Přidělení: Nerandomizované
  • Intervenční model: Crossover Assignment
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Novice Meditators

Less than 1 year of consistent meditation practice.

Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence.

Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli.

Aktivní komparátor: Advanced Meditators

More than 5 years or a minimum of 2500 hours of consistent meditation practice

Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence.

Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Acquisition of physiological data using the GLYMPHOMETER during meditation and yogic breathing sessions.
Časové okno: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Participants meeting threshold for analyzable device recordings.

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Neurofluid-related physiological measures during Shoonya meditation and Nadi Shuddhi breathing.
Časové okno: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Changes in GLYMPHOMETER-derived measures of neurofluid coupling, during Shoonya meditation and Nadi Shuddhi breathing.

(Measurement device: Glymphometer; Measure: Neurofluid coupling aka Fluid dynamics in brain)

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
Autonomic regulation during Shoonya meditation and Nadi Shuddhi breathing.
Časové okno: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Changes in heart-rate variability (HRV) during Shoonya meditation and Nadi Shuddhi breathing.

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
Very-low-frequency physiological signal characteristics
Časové okno: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Changes in predefined very-low-frequency (0.001-0.1 Hz) signal characteristics derived from GLYMPHOMETER medical™ recordings and their relationship to neurofluid-related measures.

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Differences in neurophysiological responses according to meditation experience.
Časové okno: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.

Comparison of changes in GLYMPHOMETER-derived measures of neurofluid coupling between novice and advanced meditators.

From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
Mindful Attention Awareness Scale
Časové okno: Once at Baseline. Estimated acquisition window: 5-8 minutes

We assess for change in Mindfulness levels by using a validated scale for this purpose namely, Mindfulness Attention Awareness Scale (MAAS). The scale measures the individuals' ability for receptive awareness and attention to present. This aids in evaluating any change on the individual's awareness levels after the Inner engineering intervention. We compute the MAAS scores for each participant which is a mean score for 15 item questionnaires and compare the pre & post intervention results to look for change. Participants are asked to rate on a scale of 1 (Almost Always) to 6 (Almost Never) to assess the frequency of occurrence of each experience. Mean is then computed using items from each of the 15 questions to create a MAAS score, ranging from 0 to 6. Higher MAAS scores indicate better mindfulness state.

Once at Baseline. Estimated acquisition window: 5-8 minutes
Meditation Depth Questionnaires
Časové okno: At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2

This 30-item measure assesses the subjective depth of meditation across progressively deeper experiential states. Items are typically rated on a 5-point Likert scale and are grouped into five empirically derived domains: hindrances, relaxation, personal-self/concentration, essential/transpersonal qualities, and transpersonal-self/non-duality. Together, these domains capture experiences ranging from obstacles and relaxation during meditation to focused concentration, transpersonal qualities, and experiences of diminished self-boundaries or non-dual awareness.

At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2
Correlation between GLYMPHOMETER-derived neurofluid metrics and MRI-based neurofluid dynamics (Validation of Portable Device).
Časové okno: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.

This outcome evaluates the concurrent validity of the portable device against the gold standard. The statistical method will be a correlation analysis (Pearson or Spearman, as appropriate based on data distribution).

  • Measurement 1 (Variable A): Neurofluid coupling oscillations measured via the GLYMPHOMETER medical™ device (measured as relative changes in HbO, HbR, HbT, and CSF/H2O proportional signal including interhemispheric correlation coefficient across these neurofluid compartments while gating each of them to very low frequency, respiratory and cardiac frequency bands).
  • Measurement 2 (Variable B): Global neurofluid dynamics and CSF flow measured via 3T MRI using fast fMRI and phase-contrast sequences (measured as BOLD-CSF coupling magnitude and CSF stroke volume in mL).
  • Assessment: The study will assess the correlation between the magnitude of oscillatory coupling in Measurement 1 with the absolute flow dynamics in Measurement 2 during the designated validation windows.
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
Correlation between GLYMPHOMETER-derived neurofluid metrics and plasma brain-derived biomarkers.
Časové okno: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.

This outcome evaluates the relationship between neurofluid dynamics and blood-based markers of brain clearance. The statistical method will be a correlation analysis (Pearson or Spearman).

  • Measurement 1 (Variable A): Neurofluid coupling oscillations measured via the GLYMPHOMETER medical™ device (measured as relative changes in HbO, HbR, HbT, and CSF/H2O proportional signal including interhemispheric correlation coefficient across these neurofluidic compartments while gating each of them to very low frequency, respiratory and cardiac frequency bands).
  • Measurement 2 (Variable B): Plasma concentrations of brain-derived proteins/peptides (Aβ40, Aβ42, total/phosphorylated tau, NF-L, GFAP) measured via ultra-sensitive Simoa immunoassay (measured in pg/mL).
  • Assessment: The study will assess the correlation between acute GLYMPHOMETER-derived neurofluid changes and plasma biomarker concentrations before and after intervention.
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
Qualitative assessment of meditation and breathing experiences.
Časové okno: At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2

Qualitative characterization of participant experiences using one-on-one micro-phenomenological interviews.

At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

16. listopadu 2026

Primární dokončení (Odhadovaný)

30. listopadu 2027

Dokončení studie (Odhadovaný)

30. dubna 2028

Termíny zápisu do studia

První předloženo

15. září 2026

První předloženo, které splnilo kritéria kontroly kvality

23. října 2026

První zveřejněno (Aktuální)

29. října 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

10. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

5. listopadu 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 2026P000655
  • GRT69415 (Jiné číslo grantu/financování: Inner Science Research Foundation)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .